Soluble immune checkpoint proteins and association with clinical outcomes of ccRCC patients
| Protein names | Advanced disease | Recurrence | Survival | |||
|---|---|---|---|---|---|---|
| High vs lowa | Adjusted OR (95%CI)b | P value | Adjusted HR (95%CI)c | P value | Adjusted HR (95%CI)c | P value |
| sTIM3 | 1 (reference) | 1 (reference) | 1 (reference) | |||
| 2.61 (1.07–6.40) | 0.04 | 1.65 (0.61–4.40) | 0.32 | 3.12 (1.44–6.75) | 3.94E-03# | |
| sCD27 | 1 (reference) | 1 (reference) | 1 (reference) | |||
| 0.62 (0.34–1.16) | 0.14 | 1.44 (0.68–3.03) | 0.34 | 2.80 (1.17–6.67) | 0.02 | |
| sCD28 | 1 (reference) | 1 (reference) | 1 (reference) | |||
| 0.45 (0.18–1.16) | 0.10 | 2.30 (0.96–5.51) | 0.06 | 2.71 (1.13–6.47) | 0.02 | |
| sCTLA4 | 1 (reference) | 1 (reference) | 1 (reference) | |||
| 1.75 (0.91–3.40) | 0.10 | 2.13 (1.06–4.28) | 0.03 | 1.12 (0.51–2.44) | 0.78 | |
| sIDO | 1 (reference) | 1 (reference) | 1 (reference) | |||
| 1.25 (0.62–2.54) | 0.54 | 0.48 (0.19–1.23) | 0.13 | 0.49 (0.06–3.99) | 0.51 | |
| sLAG3 | 1 (reference) | 1 (reference) | 1 (reference) | |||
| 3.36 (1.55–7.27) | 2.13E-03# | 1.38 (0.32–6.00) | 0.66 | 2.21 (0.95–5.15) | 0.07 | |
| sBTLA | 1 (reference) | 1 (reference) | 1 (reference) | |||
| 0.66 (0.33–1.33) | 0.25 | 0.61 (0.30–1.27) | 0.19 | 6.02 (2.00–18.1) | 1.39E-03# | |
| sPDL1 | 1 (reference) | 1 (reference) | 1 (reference) | |||
| 4.59 (0.91–23.3) | 0.07 | 1.51 (0.89–2.56) | 0.12 | 1.57 (0.70–3.49) | 0.27 | |
| sPDL2 | 1 (reference) | 1 (reference) | 1 (reference) | |||
| 0.53 (0.18–1.57) | 0.25 | 2.51 (1.46–4.34) | 9.33E-04# | 2.39 (0.97–5.88) | 0.06 | |
Abbreviations: OR Odds ratio, HR Hazard ratio, CI Confidence interval. Significant values in bold font
aHigh- and low-level groups dichotomized by the logistic regression spline model [12]
bAdjusted by age, gender, smoking, BMI, diabetes, and hypertension
cAdjusted by age, gender, smoking, BMI, diabetes, hypertension, histology, grade, stage and treatment
# Significant after Bonferroni adjustment for multiple testing